JPMorgan Chase & Co. Issues Pessimistic Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price

Cytokinetics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • JPMorgan lowered Cytokinetics’ price target from $103 to $100 but maintained its Overweight rating; the revised target implies 93.74% upside from the stock’s then-current price.
  • Analyst sentiment overall remains positive: 19 analysts rate the stock Buy, one Hold and one Sell, giving it a “Moderate Buy” consensus and an average price target of $106.50.
  • Cytokinetics reported quarterly EPS of -$1.37, better than the -$1.43 consensus, while revenue of $47.56 million exceeded expectations of $41.88 million. Shares traded at $51.62 on Friday.
  • Five stocks we like better than Cytokinetics.

Cytokinetics (NASDAQ:CYTK - Get Free Report) had its target price dropped by JPMorgan Chase & Co. from $103.00 to $100.00 in a report released on Friday, Benzinga reports. The firm presently has an "overweight" rating on the biopharmaceutical company's stock. JPMorgan Chase & Co.'s price target suggests a potential upside of 93.74% from the company's current price.

Other analysts have also issued reports about the stock. William Blair assumed coverage on shares of Cytokinetics in a research note on Friday, October 16th. They set an "outperform" rating for the company. Morgan Stanley raised shares of Cytokinetics from an "overweight" rating to a "buy" rating in a research note on Tuesday, September 1st. Weiss Ratings reissued a "sell (d-)" rating on shares of Cytokinetics in a research report on Thursday, October 15th. HC Wainwright reissued a "buy" rating and issued a $140.00 price objective on shares of Cytokinetics in a research note on Monday, October 19th. Finally, Citigroup raised their price target on shares of Cytokinetics from $99.00 to $105.00 and gave the company a "buy" rating in a report on Thursday, November 5th. Nineteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $106.50.

Read Our Latest Stock Report on CYTK

Cytokinetics Stock Up 0.3%

CYTK stock traded up $0.15 during mid-day trading on Friday, hitting $51.62. The company had a trading volume of 500,719 shares, compared to its average volume of 2,109,460. The company has a market capitalization of $7.19 billion, a price-to-earnings ratio of -8.55 and a beta of 0.45. The company has a 50-day moving average price of $62.35 and a 200 day moving average price of $69.53. Cytokinetics has a 12-month low of $50.32 and a 12-month high of $88.31.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The biopharmaceutical company reported ($1.37) earnings per share for the quarter, topping the consensus estimate of ($1.43) by $0.06. The business had revenue of $47.56 million during the quarter, compared to analysts' expectations of $41.88 million. The company's quarterly revenue was up 2356.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($2.55) earnings per share. As a group, analysts expect that Cytokinetics will post -5.85 EPS for the current year.

Insiders Place Their Bets

In other news, insider Jeffrey Hessekiel sold 15,106 shares of the business's stock in a transaction dated Tuesday, November 17th. The stock was sold at an average price of $52.62, for a total transaction of $794,877.72. Following the sale, the insider owned 92,837 shares in the company, valued at approximately $4,885,082.94. The trade was a 13.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Robert I. Blum sold 7,500 shares of the company's stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $53.53, for a total transaction of $401,475.00. Following the transaction, the chief executive officer owned 278,544 shares in the company, valued at approximately $14,910,460.32. This trade represents a 2.62% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 201,032 shares of company stock worth $13,320,502 in the last three months. Insiders own 2.60% of the company's stock.

Institutional Investors Weigh In On Cytokinetics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Pictet Asset Management Holding SA grew its holdings in shares of Cytokinetics by 18.4% during the third quarter. Pictet Asset Management Holding SA now owns 1,374,523 shares of the biopharmaceutical company's stock valued at $90,569,000 after buying an additional 214,060 shares during the last quarter. GW&K Investment Management LLC increased its holdings in shares of Cytokinetics by 11.1% in the third quarter. GW&K Investment Management LLC now owns 1,017,714 shares of the biopharmaceutical company's stock valued at $67,078,000 after purchasing an additional 101,607 shares during the period. Fisher Asset Management LLC raised its stake in shares of Cytokinetics by 10.1% in the third quarter. Fisher Asset Management LLC now owns 818,832 shares of the biopharmaceutical company's stock worth $53,969,000 after purchasing an additional 75,135 shares during the last quarter. ADAR1 Capital Management LLC raised its stake in shares of Cytokinetics by 17.1% in the first quarter. ADAR1 Capital Management LLC now owns 632,556 shares of the biopharmaceutical company's stock worth $41,692,000 after purchasing an additional 92,390 shares during the last quarter. Finally, Candriam S.C.A. lifted its holdings in shares of Cytokinetics by 39.3% during the third quarter. Candriam S.C.A. now owns 617,386 shares of the biopharmaceutical company's stock worth $40,841,000 after purchasing an additional 174,320 shares during the period.

Cytokinetics Company Profile

(Get Free Report)

Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company's work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.

Featured Stories

Analyst Recommendations for Cytokinetics (NASDAQ:CYTK)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cytokinetics Right Now?

Before you consider Cytokinetics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytokinetics wasn't on the list.

While Cytokinetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines